Posing a serious threat to performance, influenza A virus in swine can have a widespread impact on productivity and profitability. IAV-S is one of the top three diseases affecting pigs in all phases of production,1,2 and can lead to economic losses of more than $10 per head when present with concurrent infections.3 It can also lead to subsequent respiratory infections that can impact pig performance, including mortality and culls.
Today, however, the first live attenuated IAV-S vaccine for growing pigs is here to provide game-changing protection when and where it’s needed most. Ingelvac Provenza from Boehringer Ingelheim offers cross-protection against multiple IAV-S strains, and decreases nasal shedding, thereby reducing transmission within a population.4
With demonstrated efficacy and safety,4 as well as flexibility of timing and a method of administration that stimulates immunity at the point of natural IAV-S infection, Ingelvac Provenza fills an unmet need in the swine industry, and will establish a new way of thinking about influenza protection.
“Vaccinating pigs as young as one day of age provides protection before pigs are most vulnerable5,” says Christa Goodell, DVM, MS, PhD, Dipl ACVPM, technical manager for the Boehringer Ingelheim U.S. Swine Business. Administered intranasally, Ingelvac Provenza provides a direct means of protection at the site of natural IAV-S infection.3,6
As the first live attenuated IAV-S vaccine developed for growing pigs in the United States, Ingelvac Provenza is a bivalent H1N1 and H3N2 vaccine that offers a new level of cross-protection against influenza A virus strains, including H1N2 and more recent H3N2,4 and has been has been evaluated to reduce virus shedding in the presence of maternal antibodies.7
“This vaccine is providing protection when it is needed most, and offers cross-protection against multiple strains of IAV-S. Ingelvac Provenza reduces nasal shedding when pigs are challenged with IAV-S, which reduces transmission within the population,” Goodell explains.
Ingelvac Provenza is currently available in a 50-dose presentation. For more information, talk to your veterinarian or visit www.IngelvacProvenza.com.
References:
1. Vincent AL, Ma W, Lager KM, et al. Efficacy of intranasal administration of a truncated NS1 modified-live influenza virus vaccine in swine. Vaccine 2007;25(47):7999–8009.
2. USDA APHIS, VS, NAHMS. Swine 2012, Part II: Reference of swine health and health management in the United States. February 2016.
3. Dykhuis Haden C, Painter T, Fangman T, Holtkamp D. Assessing production parameters and economic impact of swine influenza, PRRS and Mycoplasma hyopneumoniae on finishing pigs in a large production system, in Proceedings. 43rd American Association of Swine Veterinarians Annual Meeting 2012;75–76.
4. BIAH studies #2013200, 2013232 and 2014001 published on http://productdata.aphis.usda.gov.
5. Alvarez J, Sarradell J, Kerkaert B, et al. Association of the presence of influenza A virus and porcine reproductive and respiratory syndrome virus in sow farms with post-weaning mortality. Prev Vet Med 2015;121(3–4):240–245.
6. Janke BH. Influenza A virus infections in swine: pathogenesis and diagnosis. Vet Pathol 2014;51(2):410–426.
7. Genzow M, Goodell C, Kaiser TJ, et al. Live attenuated influenza virus vaccine reduces virus shedding of newborn piglets in the presence of maternal antibody. Influenza Other Respir Viruses 2017. doi:10.1111/irv.12531.
Ingelvac Provenza is a trademark of Boehringer Ingelheim Vetmedica GmbH. ©2018 Boehringer Ingelheim Vetmedica, Inc.
